Clinical Trials

Clinical Trials

If you're interested in becoming an investigator, contact us for more information.

Spectrum conducts a range of clinical trials to bring new and novel products to the market. Please see the list below for a selected list of our trials of development drugs.

Please note, by selecting these links, you will be going to an external site that is not controlled by or affiliated with Spectrum Pharmaceuticals, Inc. These links are provided by Spectrum for informational purposes only. Spectrum accepts no responsibility for the content of any external sites.

Poziotinib clinical trials

SPI-POZ-102: Mass Balance

Phase 1 Study for the Evaluation of Excretion (Mass Balance) and Pharmacokinetics of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment with Poziotinib

SPI-POZ-202: ZENITH20

Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)

Eflapegrastim clinical trials*.

SPI-GCF-104: Same Day Dosing

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After the Same-Day, Varying Dosing Time Schedules of Eflapegrastim Administration in Patients with Breast-Cancer Receiving Docetaxel and Cyclophosphamide

SPI-GCF-202: Pediatric Patients Treated with Myelosuppressive Chemotherapy

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Patients With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

*Enrollment has been completed in the RECOVER and ADVANCE clinical studies.